3.
    发明专利
    未知

    公开(公告)号:AT208169T

    公开(公告)日:2001-11-15

    申请号:AT93908495

    申请日:1993-03-25

    Applicant: BAXTER INT

    Abstract: Implant assemblies (10) and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved boundary between the host and the implanted cells (12). The boundary has a pore size, an ultimate strength, and a metabolic transit value that assures the survival of the cells (12) during the critical ischemic period and afterward. The boundary allows the fabrication and clinical use of implant assemblies and methodologies that can carry enough cells (12) to be of therapeutic value to the host, yet occupy a relatively small, compact area within the host.

    6.
    发明专利
    未知

    公开(公告)号:ES2167332T3

    公开(公告)日:2002-05-16

    申请号:ES93908495

    申请日:1993-03-25

    Applicant: BAXTER INT

    Abstract: Implant assemblies (10) and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved boundary between the host and the implanted cells (12). The boundary has a pore size, an ultimate strength, and a metabolic transit value that assures the survival of the cells (12) during the critical ischemic period and afterward. The boundary allows the fabrication and clinical use of implant assemblies and methodologies that can carry enough cells (12) to be of therapeutic value to the host, yet occupy a relatively small, compact area within the host.

    7.
    发明专利
    未知

    公开(公告)号:PT676935E

    公开(公告)日:2002-04-29

    申请号:PT93908495

    申请日:1993-03-25

    Applicant: BAXTER INT

    Abstract: Implant assemblies (10) and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved boundary between the host and the implanted cells (12). The boundary has a pore size, an ultimate strength, and a metabolic transit value that assures the survival of the cells (12) during the critical ischemic period and afterward. The boundary allows the fabrication and clinical use of implant assemblies and methodologies that can carry enough cells (12) to be of therapeutic value to the host, yet occupy a relatively small, compact area within the host.

Patent Agency Ranking